Improved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors.

Tadmor, T ; Melamed, G ; et al.

In: Anticancer research, Jg. 44 (2024-05-01), Heft 5, S. 2109-2115

academicJournal

Background/aim: The treatment for chronic lymphocytic leukemia (CLL) has changed dramatically over the last two decades. The current study aimed to investigate the impact on overall survival (OS) and time to next treatment (TTT) among CLL patients from 1998 to 2022.

Patients and Methods: The cohort was based on data obtained from electronic medical records of Maccabi, the second largest healthcare organization in Israel. All included patients were diagnosed with CLL based on the IWCLL criteria and complete clinical, laboratory, and treatment data were available. The study encompassed 3,964 patients diagnosed with CLL during the specified study period.

Results: Patients with CLL who required therapy were divided into three eras based on the dominant treatment approach: chemotherapy alone before 2010, therapy with chemotherapy and anti-CD20 between 2010 and 2017, and therapy with targeted agents between 2017 and 2022. Median OS was 4.1 years, 7.5 years, and not reached, respectively. The six-year OS rates were 40%, 55%, and 69%, respectively, (p=0.0001). The median time to the next treatment improved from 5.5 years before 2010, to 8.3 between 2010-2017, to not reached after 2017 (p=0.0021).

Conclusion: Marked improvements in survival subsequent to fundamental changes in first-line therapy were found in patients with CLL from before 2010 to after 2017.

Titel:	Improved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors.
Autor/in / Beteiligte Person:	Tadmor, T ; Melamed, G ; Alapi, H ; Gazit, S ; Patalon, T ; Rokach, L
Zeitschrift:	Anticancer research, Jg. 44 (2024-05-01), Heft 5, S. 2109-2115
Veröffentlichung:	Attiki, Greece : International Institute of Anticancer Research ; <i>Original Publication</i>: Athens, Greece : Potamitis Press, 2024
Medientyp:	academicJournal
ISSN:	1791-7530 (electronic)
DOI:	10.21873/anticanres.17016
Schlagwort:	Female Humans Male Israel epidemiology Molecular Targeted Therapy Retrospective Studies Agammaglobulinaemia Tyrosine Kinase antagonists & inhibitors Leukemia, Lymphocytic, Chronic, B-Cell drug therapy Leukemia, Lymphocytic, Chronic, B-Cell mortality Protein Kinase Inhibitors therapeutic use Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Anticancer Res] 2024 May; Vol. 44 (5), pp. 2109-2115. MeSH Terms: Agammaglobulinaemia Tyrosine Kinase* / antagonists & inhibitors ; Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell* / mortality ; Protein Kinase Inhibitors* / therapeutic use ; Proto-Oncogene Proteins c-bcl-2* / antagonists & inhibitors ; Female ; Humans ; Male ; Israel / epidemiology ; Molecular Targeted Therapy ; Retrospective Studies Contributed Indexing: Keywords: BCL2; BTKi; CLL; Survival; chronic lymphocytic leukemia Substance Nomenclature: EC 2.7.10.2 (Agammaglobulinaemia Tyrosine Kinase) ; 0 (BCL2 protein, human) ; EC 2.7.10.2 (BTK protein, human) ; 0 (Protein Kinase Inhibitors) ; 0 (Proto-Oncogene Proteins c-bcl-2) Entry Date(s): Date Created: 20240427 Date Completed: 20240427 Latest Revision: 20240523 Update Code: 20240524

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.